Grace Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Grace Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000	Closed	-$14K	–	262
2020 Q4	$14K	Buy	+1,000	New	+$12.1K	0.01%	250

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Grace Capital's AERI Position: Q1 2021 in Review

Grace Capital sold out of Aerie Pharmaceuticals (AERI) in Q1 2021, closing a stake of 1,000 shares — an estimated $14K sold.

Grace Capital first reported a position in AERI in Q4 2020 and held it in 1 quarter. The position peaked at $14K in Q4 2020. 158 funds tracked by Wall St. Rank hold AERI as of Q1 2021.

Grace Capital reported no remaining Aerie Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Grace Capital sold 1,000 Aerie Pharmaceuticals shares in Q1 2021, an estimated $14K.
Grace Capital first reported a position in Aerie Pharmaceuticals in Q4 2020 and held it in 1 quarter.
Grace Capital's Aerie Pharmaceuticals position peaked at $14K in Q4 2020.
158 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2021.

Based on Grace Capital's 13F filing for Q1 2021, filed 6 May 2021.